Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Andreas du Bois, MD
Published: Saturday, Jun 01, 2013

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

To read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

To read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x